Feline Pemphigus Foliaceus: Welfare and Immunosuppressive Treatment

A welfare-focused guide to pemphigus foliaceus in cats, a painful autoimmune skin disease requiring aggressive immunosuppressive management.

Key Facts

Pemphigus foliaceus (PF) is the most common autoimmune skin disease in cats — it causes the immune system to attack desmoglein proteins in the skin, resulting in widespread pustule and crust formation.
Lesions typically affect the face, ears, footpads, and nail beds — footpad involvement causes intense pain on walking, and affected cats may become severely lame.
The welfare burden of untreated PF is significant — chronic skin pain, secondary infection, and the psychological distress of altered normal sensory experience all reduce quality of life.
Drug-induced pemphigus foliaceus occurs in cats — certain flea prevention products (historically methimazole) have been associated with PF induction; medication history is critical in diagnosis.
Treatment requires immunosuppression: prednisolone alone or combined with chlorambucil, doxycycline, and niacinamide — response rates vary, with 60-70% achieving good disease control.
Cats in PF remission require long-term maintenance immunosuppression — relapse on tapering is common and requires dose adjustment rather than treatment cessation.
Quality of life monitoring in PF cats should include: mobility assessment, appetite, grooming behavior, and owner-reported comfort — weekly scoring helps guide treatment decisions.

Welfare Considerations

Pemphigus foliaceus causes significant skin pain and mobility impairment in affected cats — footpad lesions in particular can make walking intensely uncomfortable. Early diagnosis and aggressive immunosuppressive treatment achieve disease control in most cases. Any cat with rapidly spreading facial or footpad crusting, especially with signs of pain, deserves prompt dermatological assessment.

What You Can Do

Seek prompt veterinary assessment for any cat with widespread facial or footpad crusting and signs of discomfort
Begin immunosuppressive treatment promptly — delays allow progression and secondary infection to compound suffering
Monitor drug-induced PF cases carefully — discontinuing the triggering medication is the first step
Use quality-of-life scoring tools to guide treatment decisions and end-of-life planning in refractory cases